Literature DB >> 22067400

Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

Monique Maas1, Regina G H Beets-Tan, Doenja M J Lambregts, Guido Lammering, Patty J Nelemans, Sanne M E Engelen, Ronald M van Dam, Rob L H Jansen, Meindert Sosef, Jeroen W A Leijtens, Karel W E Hulsewé, Jeroen Buijsen, Geerard L Beets.   

Abstract

PURPOSE: Neoadjuvant chemoradiotherapy for rectal cancer can result in complete disappearance of tumor and involved nodes. In patients without residual tumor on imaging and endoscopy (clinical complete response [cCR]) a wait-and-see-policy (omission of surgery with follow-up) might be considered instead of surgery. The purpose of this prospective cohort study was to evaluate feasibility and safety of a wait-and-see policy with strict selection criteria and follow-up. PATIENTS AND METHODS: Patients with a cCR after chemoradiotherapy were prospectively selected for the wait-and-see policy with magnetic resonance imaging (MRI) and endoscopy plus biopsies. Follow-up was performed 3 to 6 monthly and consisted of MRI, endoscopy, and computed tomography scans. A control group of patients with a pathologic complete response (pCR) after surgery was identified from a prospective cohort study. Functional outcome was measured with the Memorial Sloan-Kettering Cancer Center (MSKCC) bowel function questionnaire and Wexner incontinence score. Long-term outcome was estimated by using Kaplan-Meier curves.
RESULTS: Twenty-one patients with cCR were included in the wait-and-see policy group. Mean follow-up was 25 ± 19 months. One patient developed a local recurrence and had surgery as salvage treatment. The other 20 patients are alive without disease. The control group consisted of 20 patients with a pCR after surgery who had a mean follow-up of 35 ± 23 months. For these patients with a pCR, cumulative probabilities of 2-year disease-free survival and overall survival were 93% and 91%, respectively.
CONCLUSION: A wait-and-see policy with strict selection criteria, up-to-date imaging techniques, and follow-up is feasible and results in promising outcome at least as good as that of patients with a pCR after surgery. The proposed selection criteria and follow-up could form the basis for future randomized studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067400     DOI: 10.1200/JCO.2011.37.7176

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  267 in total

Review 1.  [The role of cross-sectional imaging in staging of rectal cancer].

Authors:  A O Schäfer; M Langer; T Baumann
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

2.  T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer.

Authors:  Ewelina Kluza; Esther D Rozeboom; Monique Maas; Milou Martens; Doenja M J Lambregts; Jos Slenter; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

3.  Management of adenomas within the area of rectal cancer that develop complete pathological response.

Authors:  Angelita Habr-Gama; Maria Regina Vianna; Guilherme P São Julião; Viviane Rawet; Joaquim Gama-Rodrigues; Igor Proscurshim; Jacyara Alves; Laura M Fernandez; Rodrigo O Perez
Journal:  Int J Colorectal Dis       Date:  2015-08-05       Impact factor: 2.571

Review 4.  Complete radiotherapy response in rectal cancer: A review of the evidence.

Authors:  Daniel G Couch; David M Hemingway
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 5.  Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging.

Authors:  Stephanie E Combs; Fridtjof Nüsslin; Jan J Wilkens
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

6.  Non-invasive MR assessment of macroscopic and microscopic vascular abnormalities in the rectal tumour-surrounding mesorectum.

Authors:  Ewelina Kluza; Jean-Paul J E Kleijnen; Milou H Martens; Dorit Rennspiess; Monique Maas; Cécile R L P N Jeukens; Robert G Riedl; Axel zur Hausen; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

7.  [Radiotherapy of rectal cancer].

Authors:  M Wolf; F Zehentmayr; C Belka
Journal:  Radiologe       Date:  2012-06       Impact factor: 0.635

Review 8.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 9.  Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review.

Authors:  Alejandro Recio-Boiles; Hytham Hammad; Krisha Howell; Bobby T Kalb; Valentine N Nfonsam; Aaron J Scott; Hani M Babiker; Emad Elquza
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 10.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.